OnKure Therapeutics
OKUR
38 hedge funds and large institutions have $137M invested in OnKure Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 38 → 38 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.01% less ownership
Funds ownership: 7.53% → 7.52% (-0.01%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
20% less capital invested
Capital invested by funds: $171M → $137M (-$33.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.49M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$948K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$849K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$412K |
| 5 |
State Street
Boston,
Massachusetts
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$2.11M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$513K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$424K |
| 4 |
PCM
Pinz Capital Management
New York
|
-$320K |
| 5 |
Morgan Stanley
New York
|
-$229K |
OKUR Hedge Fund Activity: Q3 2021 in Review
38 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2021, worth a combined $137M — down 20% from $171M a quarter earlier.
Fund positioning in OKUR was balanced in Q3 2021: 4 funds opened new positions, 4 closed out, 10 added to existing stakes and 11 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.49M. The largest seller was Nicholas Investment Partners, exiting entirely with an estimated $2.11M sold.
- 38 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $137M of OnKure Therapeutics stock for Q3 2021, down 20% quarter-over-quarter.
- 4 funds opened new OnKure Therapeutics positions in Q3 2021 and 4 closed out, a net change of 0 holders.
- The largest OnKure Therapeutics buyer in Q3 2021 was Ikarian Capital, an estimated $1.49M added.
- The largest OnKure Therapeutics seller in Q3 2021 was Nicholas Investment Partners, an estimated $2.11M sold.
Based on aggregated 13F filings for Q3 2021.